8-K: NovaBay Pharmaceuticals to Divest DERMAdoctor Skincare Business for $1.07 Million, Streamlining Operations

NovaBay Pharmaceuticals is selling its DERMAdoctor skincare business for $1.07 million to reduce operating expenses and focus on its core eyecare business.

Summary

• NovaBay Pharmaceuticals has entered into an agreement to sell its DERMAdoctor skincare business for $1.07 million.
• The sale includes all product inventory and is expected to close by the end of the first quarter of 2024.
• NovaBay will provide transitional services for 90 days post-sale.
• The divestiture is aimed at reducing quarterly operating expenses and providing much-needed cash.
• The company's projections for DERMAdoctor sales and profitability were not met.
• The company will focus on its core Avenova business and strategic opportunities.
• The company expects to report $3.7 million in net sales for the fourth quarter of 2023, with $0.9 million from DERMAdoctor and $2.8 million from eyecare and wound care.
• The operating loss for the fourth quarter of 2023 is expected to be approximately $3.2 million, primarily due to a $2.7 million loss in the DERMAdoctor segment.
• This loss includes a $2.5 million non-cash impairment of goodwill and other assets.
• Cash used in operating activities for the fourth quarter of 2023 was $0.3 million.
• For the full year 2023, net sales are expected to be $14.7 million, with $3.6 million from DERMAdoctor and $11.1 million from eyecare and wound care.
• The operating loss for the 2023 fiscal year is expected to be approximately $7.4 million, including a $3.8 million loss in the DERMAdoctor segment.
• NovaBay's cash balance as of December 31, 2023, was $3.1 million, with $1.1 million in outstanding convertible notes.
• As of March 12, 2024, there were 30,098,150 shares of NovaBay's common stock outstanding.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the divestiture of a business segment, significant losses, and the need for cash. However, the strategic shift and focus on the core business are positive aspects.

Positives

• The sale of DERMAdoctor will reduce quarterly operating expenses.
• The transaction will provide NovaBay with much-needed cash.
• The divestiture allows NovaBay to streamline its business and focus on its core Avenova business.
• The company can now pursue new strategic opportunities with greater growth potential.
• The company has a co-promotion partnership with Eyenovia.

Negatives

• DERMAdoctor's sales and profitability projections were not realized.
• The DERMAdoctor segment had a significant operating loss of $2.7 million in Q4 2023.
• The DERMAdoctor segment loss includes a $2.5 million non-cash impairment of goodwill and other assets.
• The company had a $7.4 million operating loss for the 2023 fiscal year.
• The company used $0.3 million in cash for operating activities in Q4 2023.

Risks

• The company may not be able to successfully complete its financing initiatives.
• The company may not be able to continue operating as a going concern.
• There is a potential inability to close the sale of DERMAdoctor within the expected timeframe, or at all.
• The company may be unable to maintain the listing of its common stock on the NYSE American.
• The company's revenues may not be sufficient to meet its cash needs.

Future Outlook

The company plans to report 2023 fourth quarter and full year financial results and to hold an investment community conference call in the coming weeks. The company will focus on its core Avenova business and strategic opportunities.

Management Comments

• This sale will reduce our quarterly operating expenses and provide us with much-needed cash during this challenging capital market environment, said Justin Hall, CEO of NovaBay.
• It also streamlines our business by placing us in a better position to pursue new strategic opportunities that have greater potential for growth.
• Unfortunately, our projections for DERMAdoctor sales and profitability were not realized.
• This divestiture aligns with our strategy of executing on more promising transactions that involve our core Avenova business such as our recently announced co-promotion partnership with Eyenovia.

Industry Context

The divestiture reflects a strategic shift in the company's focus from direct-to-consumer skincare to its core eyecare business, aligning with a trend of companies streamlining operations to focus on core competencies. The co-promotion partnership with Eyenovia also indicates a move towards strategic collaborations within the eyecare sector.

Comparison to Industry Standards

• The sale of DERMAdoctor for approximately $1.07 million is a relatively small transaction compared to larger acquisitions in the skincare industry, which often involve multi-million or billion-dollar deals.
• The $2.5 million non-cash impairment of goodwill and other assets in the DERMAdoctor segment is a significant write-down, indicating that the business was not performing as expected and is not uncommon in situations where a business unit is underperforming.
• The company's focus on its core Avenova business is similar to other companies that divest non-core assets to improve profitability and focus on their strengths.
• The co-promotion partnership with Eyenovia is a common strategy in the pharmaceutical industry to expand market reach and leverage existing sales channels, similar to other partnerships between companies with complementary products.

Stakeholder Impact

• Shareholders will see a reduction in operating expenses and a focus on the core business, but also a loss from the DERMAdoctor segment.
• Employees of DERMAdoctor will be impacted by the sale of the business.
• Customers of DERMAdoctor will be transitioned to the new owner.
• Suppliers of DERMAdoctor will be impacted by the sale of the business.

Next Steps

• Close the sale of the DERMAdoctor business by the end of the first quarter of 2024.
• Provide transitional services for 90 days post-sale.
• Report 2023 fourth quarter and full year financial results.
• Hold an investment community conference call in the coming weeks.
• Focus on the core Avenova business and strategic opportunities.

Key Dates

Keywords

DERMAdoctor, NovaBay Pharmaceuticals, skincare, divestiture, eyecare, Avenova, operating expenses, financial results, asset sale, convertible notes